ALK and non-small cell lung carcinoma: In October 2016, atezolizumab was approved for the patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities, based on the results of the phase 2 POPLAR [73] and phase 3 OAK trials [74].